The P2X7 Receptor, a Multifaceted Receptor in Alzheimer's Disease

Int J Mol Sci. 2023 Jul 21;24(14):11747. doi: 10.3390/ijms241411747.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by impaired episodic memory and two pathological lesions: amyloid plaques and neurofibrillary tangles. In AD, damaged neurons and the accumulation of amyloid β (Aβ) peptides cause a significant release of high amounts of extracellular ATP, which acts as a danger signal. The purinergic receptor P2X7 is the main sensor of high concentrations of ATP, and P2X7 has been shown to be upregulated in the brains of AD patients, contributing to the disease's pathological processes. Further, there are many polymorphisms of the P2X7 gene that impact the risk of developing AD. P2X7 can directly modulate Aβ plaques and Tau protein lesions as well as the inflammatory response by regulating NLRP3 inflammasome and the expression of several chemokines. The significant role of microglial P2X7 in AD has been well established, although other cell types may also be important in P2X7-mediated mechanisms. In this review, we will discuss the different P2X7-dependent pathways involved in the development of AD.

Keywords: Alzheimer’s disease; chemokines; cytokines; inflammation; microglia; purinergic receptor.

Publication types

  • Review

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / genetics
  • Amyloid beta-Peptides / metabolism
  • Humans
  • Microglia / metabolism
  • Neurodegenerative Diseases* / metabolism
  • Receptors, Purinergic P2X7 / genetics
  • Receptors, Purinergic P2X7 / metabolism

Substances

  • Adenosine Triphosphate
  • Amyloid beta-Peptides
  • Receptors, Purinergic P2X7
  • P2RX7 protein, human

Grants and funding

This research was funded by Institut National de la Santé et de la Recherche Médicale (INSERM); Sorbonne University; Agence Nationale pour la Recherche (ANR); Programme Investissements d’Avenir IHU FOReSIGHT, grant number ANR-18-IAHU-0001; Union Nationale des Aveugles et Déficient Visuels (UNADEV); and Retina France. The APC was funded by Union Nationale des Aveugles et Déficient Visuels (UNADEV).